Eli Lilly (NYSE:LLY) is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, ...
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...
“I am gobsmacked that Lilly is seeking confidential patient medical records to build a case against the very therapies that ...
It started in 2022, when the FDA placed the active ingredients in Eli Lilly’s Mounjaro and Zepbound, and Novo’s Ozempic and Wegovy, on its shortage list, a designation that opened the door for ...
One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...
To paraphrase a Shakespeare quote, bad news and misfortune tend to come in groups. But that may also apply to good news. Just ask Eli Lilly (NYSE: LLY), a pharmaceutical company that has been ...
Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...
Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...
We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...